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Tenofovir disoproxil fumarate (tenofovir DF) was studied in combination with rifampin in 24 healthy
subjects in a multiple-dose, open-label, single-group, two-period study. All subjects were given tenofovir DF at
300 mg once a day (QD) from days 1 to 10 (period 1). From days 11 to 20 the subjects received tenofovir DF
at 300 mg combined with rifampin at 600 mg QD (period 2). The multiple-dose pharmacokinetics of tenofovir
(day 10 and 20) and rifampin (day 20) were assessed. The drug-related adverse events (AEs) experienced
during this study were mostly mild. Only one grade 3 AE possibly or probably related to the treatment (raised
liver enzyme levels) occurred during period 2; the subject was withdrawn from the study. Pharmacokinetic data
for 23 subjects were thus evaluable. Point estimates for the mean ratios of tenofovir with rifampin versus
tenofovir alone for the area under the concentration-time curve from time zero to 24 h (AUC0-24), the maximum
concentration of drug in plasma (Cmax), and the minimum concentration of drug in plasma (Cmin) were 0.88,
0.84, and 0.85, respectively. The 90% classical confidence intervals for AUC0-24, Cmax, and Cmin were 0.84 to
0.92, 0.78 to 0.90, and 0.80 to 0.91, respectively, thus suggesting pharmacokinetic equivalence. Similarly,
coadministration of rifampin and tenofovir DF did not result in changes in the values of the tenofovir
pharmacokinetic parameters. For rifampin, the values of the pharmacokinetic parameters found in this study
were comparable to those found in the literature, indicating that tenofovir DF has no effect on the pharma-
cokinetics of rifampin. In conclusion, adaptation of either the rifampin or the tenofovir DF dose for the
simultaneous treatment of tuberculosis and human immunodeficiency virus (HIV) infection in HIV-infected
patients is probably not required.
Coinfection with Mycobacterium tuberculosis and human im-
munodeficiency virus (HIV) is frequent, particularly in Africa
and Asia (3, 14, 18). Simultaneous treatment of tuberculosis
and HIV infection may lead to complex combination therapy.
Rifampin is a drug of choice for the treatment of tuberculosis.
Rifampin is known to have major pharmacokinetic interactions
with HIV protease inhibitors and nonnucleoside reverse tran-
scriptase inhibitors (8, 10, 12, 13, 16, 17). Tenofovir disoproxil
fumarate (tenofovir DF) is the first drug from a new class of
anti-HIV agents (nucleotide reverse transcriptase inhibitors)
that has been recently approved for use for the treatment of
HIV infections in adults. However, no data are available re-
garding its pharmacokinetics in combination with tuberculo-
static drugs, in particular, rifampin. No influence of rifampin
on the pharmacokinetics of tenofovir is expected, because both
drugs are metabolized and eliminated in different ways. Teno-
fovir is eliminated unchanged by glomerular filtration and ac-
tive tubular secretion (1, 6), while rifampin is extensively me-
tabolized by intestinal and hepatic metabolism (4). However, a
pharmacokinetic interaction cannot be excluded.
The clinical trial described here was designed to explore the
pharmacokinetics of tenofovir DF with and without rifampin in
an effort to establish whether there is a need to adjust the
dosage of either medication when the two medications are
used for the treatment of patients coinfected with M. tubercu-
losis and HIV.
MATERIALS AND METHODS
Study design. The present study was designed to evaluate the effect of 600 mg
of rifampin on the pharmacokinetics of 300 mg of tenofovir DF and also to assess
whether tenofovir DF has a substantial impact on steady-state exposure to
rifampin. This study was a multiple-dose, open-label, single-group, two-period
study with 24 healthy volunteers. First, the subjects received tenofovir DF at 300
mg once daily (QD) for 10 days (period 1). At study day 10, a steady-state 24-h
pharmacokinetic curve was obtained for tenofovir. During the second period of
the study (period 2), tenofovir DF at 300 mg was combined with rifampin at 600
mg QD, again for 10 days. At study day 20, 24-h steady-state pharmacokinetic
curves were obtained for tenofovir and rifampin. During the study both tenofovir
DF and rifampin had to be taken with breakfast. On the days prior to study days
9 and 19, the subjects reported to the study center for direct observation of
dosing with the medications with a standardized breakfast. Subsequently, on the
evenings of study days 9 and 19 the subjects remained at the study center for two
overnight stays and remained at the study center until the mornings of study days
11 and 21, respectively. On days 9, 10, 11, 19, and 20 the subjects received a
standardized breakfast of 550 kcal (two slices of white bread, 15 g of low-fat
margarine, 14 g of jelly, 150 ml of orange juice, and 150 ml of skim milk). The
medication was administered immediately after breakfast with 200 ml of tap
water. All other meals and snacks on the pharmacokinetic study days were also
standardized. When the subjects took the medication at home, study drugs were
administered with breakfast (at least two and at most three slices of wheat
bread).
No crossover design was used in this study because rifampin could lead to
considerable carryover effects, due to its long-lasting cytochrome P450-inducing
effect. To eliminate this effect a longer washout period would be necessary, but
this would have significantly prolonged the duration of the study and would have
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led to difficulties with subject recruitment and retention. This study was reviewed
and approved by the independent ethics committee Arnhem-Nijmegen. Written
informed consent was obtained from each study subject prior to the conduct of
any study-related activity.
Study subjects. Twenty-four healthy male and female subjects were eligible for
inclusion in the study. The subjects could be between 18 and 65 years of age with
a body weight of at least 50 kg and in good age-appropriate health condition, as
established by the individual’s medical history; a physical examination; electro-
cardiography; and the results of biochemistry, hematology, and urine analyses
within the 3 weeks prior to administration of the first dose. Other inclusion
criteria were an ability to sign informed consent voluntarily and a willingness to
refrain from the use of contact lenses during the treatment with rifampin. Ex-
clusion criteria were as follows: positive tests for HIV, hepatitis B virus, or
hepatitis C virus; a tuberculin skin test reaction of more than 15 mm or a
tuberculin skin test reaction of 1 to 15 mm with a chest X ray with abnormalities
consistent with tuberculosis; pregnancy; breast-feeding; the lack of adequate
contraception (e.g., hysterectomy; bilateral tubal ligation; the use of an intra-
uterine device, total abstinence, or double-barrier methods; or a postmenopausal
state for 2 years) among female subjects of childbearing potential; a creatinine
clearance rate 60 ml/min; or a serum creatinine level above 133 mol/liter.
Sampling for pharmacokinetic studies. For determination of the tenofovir and
rifampin concentrations in blood plasma, samples of 5 ml of blood, recovered to
obtain at least 2 ml of plasma, were collected in heparinized hard plastic tubes at
the following times: just before drug intake (predosing); on day 10 and day 20;
and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24 h after drug intake. The blood samples
were centrifuged at 2,500  g for 10 min at 4°C. The plasma was divided into
equal portions, transferred to polypropylene tubes, and stored at 18°C for
samples containing tenofovir and 70°C for samples containing rifampin.
Safety. Blood samples for serum biochemistry analyses, including tests for
glucose and hematologic analyses, and urine samples for urinalysis were taken on
study days 1, 4, 9, 11, 15, 19, and 21. These samples were taken while the subjects
were in a fasting condition. In females of childbearing potential, testing of blood
for human chorionic gonadotropin was performed at the screening visit and on
study days 11 and 21. An instant test of urine for human chorionic gonadotropin
was performed on study day 1. To avoid possible interactions between drugs of
abuse and study drugs, a urine drug screen was performed at the screening visit
and on study days 1, 9, and 19 with the Instacheck Multi-Drug Screen panel
(Forefront Diagnostics, San Diego, Calif.). Vital signs for cardiovascular safety
(systolic and diastolic blood pressures and heart rate) were monitored, and an
electrocardiogram was recorded at the screening visit. The medical and nursing
staff of the trial center monitored the subjects for adverse events (AEs) through-
out their confinement. Subjects voluntarily reported any AE or reported AEs in
response to general questioning. All AEs occurring between the first intake of
the trial medication(s) and the end of the trial were reported. The relationship
of the trial drug(s) was not related or unlikely to be related to the trial drug(s)
if evidence existed that the AE had a source other than the trial drug(s). AEs
were recorded as possibly or probably related to the trial drug(s) if a temporal
relationship existed between the event onset and administration of the trial
drug(s) and there was no evidence of an alternative cause for the event.
The severities of the AEs were recorded and graded according to the common
toxicity criteria (grades 1, 2, 3, and 4) of the National Institute of Allergy and
Infectious Diseases.
Bioanalysis. Tenofovir concentrations were determined by using a validated
high-performance liquid chromatography assay with a fluorimetric detector by a
modified method (5). A Symmetry Shield RP18 analytical column (3.5 m; 150
by 4.6 mm; Waters, Etten-Leur, The Netherlands) was used. The method in-
volved extraction of the drug and the internal standard, adefovir (Gilead Sci-
ences, Foster City, Calif.), from 100 l of human plasma by adding 200 l of
acetonitrile. The supernatant was evaporated, and 200 l of 0.34% chloroacet-
aldehyde in 50 mM acetate buffer (pH 4.5) was added. Fluorescent compounds
were obtained by 40 min of incubation at 90°C. After the samples were cooled at
20°C for 5 min, 10 l was injected onto the column. The flow rate was 1 ml/min.
The mobile phase consisted of a mixture of phosphate buffer (50 mM; pH 6.8)
and acetonitrile (96:4; vol/vol) that resolved the drug and the internal standard
from endogenous matrix components and other drugs that were possibly present.
Chromatographic analysis was performed at 30°C under isocratic conditions with
extinction and emission wavelengths of 232 and 420 nm, respectively. The reten-
tion times of tenofovir and the internal standard, adefovir, were 6.34 and 3.90
min, respectively. The concentrations of the quality controls used were 0.03, 0.21,
and 1.05 mg/liter. The intra- and interassay coefficients of variation were less
than 4% for all quality controls. The lower limit of quantification was 0.0045
mg/liter. The rate of recovery of tenofovir from human plasma was 86%.
Rifampin concentrations were determined by using a previously described (12)
high-performance liquid chromatography method. The concentrations of the
quality controls used were 2.85, 9.5, and 24 mg/liter. The intra- and interassay
coefficients of variation were less than 1.1% for all quality controls. The lower
limit of quantification was 0.50 mg/liter. Samples from the same subject were
analyzed by use of the same standard curve.
Pharmacokinetic analysis. Pharmacokinetic parameters for tenofovir and ri-
fampin were calculated by noncompartmental methods by use of the WinNonlin
software package (version 4.1; Pharsight Corporation, Mountain View, Calif.)
and the log/linear trapezoidal rule. On the basis of the individual plasma con-
centration-time data, the following pharmacokinetic parameters were deter-
mined: the area under the plasma concentration-time curve (AUC) from time
zero to 24 h (AUC0-24; in milligram  hour per liter), the maximum concentration
of drug in plasma (Cmax; in milligrams per liter), the time to reach Cmax (Tmax;
in hours), the minimum concentration drug in plasma (Cmin; in milligrams per
liter), the apparent elimination half-life (t1/2; in hours), and the apparent oral
clearance (CL/F; in liters per hour). AUC0–C*, where C* is the last quantifiable
concentration, was calculated for rifampin. Cmin and CL/F were not calculated
for rifampin.
Statistical analysis. Statistical analyses were performed with SPSS software
(version 11.0; SPSS Inc., 1989 to 1999). Descriptive statistics were calculated with
Excel 2000 software (Microsoft Corporation, 1985 to 1999). Evaluation of the
AUC0–24 and the Cmax of tenofovir was the main objective of this trial. These
parameters are considered the primary characteristics for the extent and the rate
of drug absorption, respectively. The bioequivalence of tenofovir was determined
by comparing the values of the relevant pharmacokinetic parameters obtained
with the test treatment (tenofovir DF and rifampin on study day 20) to those
obtained with the reference treatment (tenofovir DF alone on study day 10) by
using the following statistical methods. The AUC0-24, Cmax, and Cmin of tenofovir
were reported for study day 10 and study day 20 together by use of the ratios of
the values on study day 20/values on study day 10. The arithmetic means and
standard deviations are given for study day 20 and study day 10. The geometric
mean ratios and 90% classical confidence intervals for AUC0-24, Cmax, and Cmin
were calculated. Treatments were considered bioequivalent if the respective 90%
classical confidence intervals for AUC0-24 and Cmax were included within a
bioequivalence range of 80 to 125% (20). The values of the pharmacokinetic
parameters for rifampin were compared with data from the literature by the use
of descriptive statistics. The study was powered for the tenofovir Cmax by using
nQuery software, and a sample size of 15 was required to achieve an 80% power
to reject the null hypothesis that the two treatments are not equivalent in favor
of the alternative hypothesis that the means of the two treatments are equivalent
when the expected difference is 0.000. By this approach, a sample size of 15
would provide a 93% power for AUC0-24. By considering the possibility that the
subjects would drop out and/or that some difficulties with sample or pharmaco-
kinetic analysis with some subjects would occur, 24 subjects were enrolled in this
study.
RESULTS
Demographics. Twenty-four subjects (13 males, 11 females)
were enrolled in this trial. One male subject was black; all
other subjects were Caucasian. The mean age of the subjects
was 41 years (range, 20 to 63 years). The mean body weight was
77 kg (range, 58 to 97 kg), and the mean height was 1.75 m
(range, 1.59 to 1.88 m).
Pharmacokinetics. The pharmacokinetic evaluation was
based on data sets for subjects that completed the study on
both study days (study days 10 and 20). Data for 23 subjects
were included in the pharmacokinetic analysis of tenofovir and
rifampin. Table 1 provides a summary of the values of the
pharmacokinetic parameters for tenofovir, including the arith-
metic means, geometric mean ratios, and 90% confidence in-
terval estimates for the pharmacokinetic parameters for teno-
fovir alone (study day 10) and tenofovir in combination with
rifampin (study day 20). The tenofovir AUC0-24, Cmax, and
Cmin were lower in period 2 when tenofovir DF was coadmin-
istered with rifampin. However, the magnitudes of these dif-
ferences were small, with geometric mean ratios (90% confi-
dence intervals) of 0.88 (0.84 to 0.92), 0.84 (0.78 to 0.90), and
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0.85 (0.80 to 0.91) for AUC0-24, Cmax, and Cmin, respectively,
suggesting pharmacokinetic equivalence when tenofovir DF
was dosed with or without rifampin.
Figure 1 illustrates the effects of rifampin on the mean
concentration-time profiles of tenofovir. Table 2 presents the
values of the pharmacokinetic parameters for rifampin when it
was combined with tenofovir and the values of the pharmaco-
kinetic parameters of rifampin from the literature (4, 15). The
values of the pharmacokinetic parameters for rifampin when it
was combined with tenofovir are comparable to those in the
literature when rifampin is administered with food, suggesting
that tenofovir has no influence on rifampin exposure.
Safety. All 24 subjects reported one or more AEs at some
time during the study. No subject experienced a grade 4 AE or
a serious AE. In total, 160 grade 1 or grade 2 AEs were
reported. A total of 102 AEs were judged to be possibly or
probably related to a study drug(s). During treatment with
tenofovir DF (period 1), 33 possibly or probably related AEs
were reported, while during period 2 (tenofovir DF combined
with rifampin), 69 possibly or probably related AEs were re-
ported. Of the 69 AEs reported during period 2, 24 AEs were
related only to rifampin. Each subject reported discoloration
of the urine. Most of the study drug-related AEs were mild
(85% were grade 1 in severity). All AEs resolved after the
withdrawal of treatment.
All 24 subjects completed treatment period 1 (tenofovir DF
alone). The most common AEs that were reported during
treatment with tenofovir DF were fatigue, headache, and gas-
trointestinal disorders.
During period 2 one subject was withdrawn from the study
due to several complaints, which were rash, headaches, abdom-
inal disorders, fatigue, somnolence, and dizziness. The study
medications were stopped on study day 15. At the follow-up
visit, 5 days later, the subject developed elevated liver enzyme
levels, which were judged to be a grade 3 AE. Nine days after
the first follow-up visit the liver enzyme levels returned to
normal. The AEs that occurred during the combination treat-
ment with tenofovir DF and rifampin consisted mainly of flu-
like symptoms (e.g., fatigue, headache, and gastrointestinal
disorders) and urine discoloration, which are well-known AEs
of rifampin (7).
No clinically significant hematology or urinalysis values were
observed in this study.
DISCUSSION
This study was designed to investigate whether rifampin
influences the pharmacokinetics of tenofovir. The study
showed that bioequivalence could be suggested for tenofovir
DF combined with rifampin and tenofovir DF given alone and
that the combination of tenofovir DF with rifampin was gen-
erally well tolerated, as only one patient prematurely discon-
tinued from study.
The confidence intervals for AUC and Cmin were 0.84 to 0.92
and 0.80 to 0.91, respectively, while the confidence interval was
FIG. 1. Plasma tenofovir concentrations. ■, tenofovir concentra-
tion on study day 10 (n  23) after administration of 300 mg QD; ,
tenofovir concentration on study day 20 (n  23) after administration
of 300 mg combined with rifampin at 600 mg QD. Data are presented
as means, and error bars indicate standard deviations.
TABLE 1. Pharmacokinetics of tenofovir
Study day and
statisticsa
AUC0–24
(mg  h/liter) Cmax (mg/liter) Cmin (mg/liter) Tmax (h)
c t1/2 (h) CL/F
Day 10 3.56  0.77 (3.48)b 0.36  0.080 (0.36) 0.071  0.016 (0.069) 1.0 (1.0–3.0) 13.8 4.53 (13.2) 88.1  19.0 (86.2)
Day 20 3.11  0.57 (3.06) 0.30  0.060 (0.30) 0.060  0.011 (0.059) 1.0 (1.0–2.0) 11.6 2.77 (11.2) 99.8  20.3 (98.0)
Geometric mean
ratio for day
20/day 10
(90% CI)
0.88 (0.84–0.92) 0.84 (0.78–0.90) 0.85 (0.80–0.91)
a n  23. CI, confidence interval.
b Values are arithmetic means  standard deviations (geometric means), unless indicated otherwise.
c Values are medians (ranges).
TABLE 2. Pharmacokinetics of rifampin
Parameter
Value on day
20 (this study)
(n  23)
Value in the
literature
(n  14)a
Tmax (h) 2.4 (0.6)
b 4.43 (1.11)
Cmax (mg/liter) 10.9 (3.0) 7.27 (2.25)
AUC0–12 (mg  h/liter) 43.27 (15.28) 50.97 (14.27)
t1/2 (h) 1.5 (0.3)
a The data are from reference 15 and are for subjects who received rifampin
with breakfast.
b Values are means (standard deviations).
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0.78 to 0.90 for Cmax. By definition, bioequivalence was proven
for AUC and Cmin but was only suggested for Cmax (20).
The tenofovir DF dose used in this study (300 mg QD) is the
dose recommended for the treatment of HIV infection in
adults (11). The rifampin dose used (600 mg QD) is an ac-
cepted regimen for the treatment of tuberculosis in patients
weighing more than 50 kg (7). A previous study (2) has shown
that steady-state conditions for rifampin are generally achieved
after the sixth daily dose of rifampin at 600 mg. To ensure the
achievement of steady-state pharmacokinetics, subjects were
given tenofovir DF combined with rifampin for 10 days before
pharmacokinetic assessment.
The reason for the lower observed tenofovir levels is un-
known. Several mechanisms could contribute to this interac-
tion. Because tenofovir is not metabolized and is eliminated
unchanged by a combination of glomerular filtration and active
tubular secretion (1, 6), it is unlikely that the inducing effect of
rifampin on hepatic and intestinal cytochrome P450 enzymes
(especially CYP3A4) (8) is the mechanism responsible for this
effect. This is supported by no apparent changes in the teno-
fovir t1/2 and no clinically relevant effects of rifampin on the
tenofovir Cmin.
Similarly, as tenofovir minimally binds to proteins in human
plasma or serum (0.7 and 7.2%, respectively) (11), altered
distribution is also probably not the mechanism responsible for
the pharmacokinetic differences observed. As the decrease in
the tenofovir Cmax was 16% while the decrease in AUC0–24 was
12%, the cause may be in the process of tenofovir DF or
tenofovir absorption. Rifampin has been shown to be an in-
ducer of the efflux transporter P glycoprotein (9). No informa-
tion exists in the literature that P glycoprotein plays a role in
the process of absorption of tenofovir in vivo. However, van
Gelder et al. (19) have described the transport of tenofovir DF
by a P-glycoprotein-related efflux mechanism in the Caco-2
system.
AEs led to one discontinuation in this study; grade 3 eleva-
tions in hepatic enzyme levels were reported after the medi-
cation was stopped during period 2, when tenofovir DF was
combined with rifampin. Liver disturbance is a well-known side
effect of rifampin. Gastrointestinal disorders are well-known
AEs of both tenofovir and rifampin and occurred in a total of
46% of the study subjects during both study periods. During
period 2 all subjects reported discoloration of their urine,
which is a well-known AE of rifampin (7).
Some additional considerations are important for the ex-
trapolation of the results of this study to patients. First, it
should be noted that all the participants in this study were
healthy subjects. It cannot be excluded that the pharmacoki-
netics of tenofovir and rifampin are different in HIV-infected
patients coinfected with M. tuberculosis due to one or both of
the diseases. Second, 23 of the 24 subjects of this study were
Caucasian. Race might have an effect on the values of the
pharmacokinetic parameters for tenofovir, although the avail-
able pharmacokinetic data do not indicate substantial differ-
ences with regard to race (11). Finally, the subjects in this study
were given tenofovir DF and rifampin only, while HIV-in-
fected patients coinfected with M. tuberculosis are treated with
other antiretroviral and tuberculostatic drugs, which can cause
interactions.
In conclusion, the data from this study demonstrate that the
addition of rifampin to tenofovir DF is well tolerated, and the
small decrease in plasma tenofovir levels during combination
treatment suggests that these drugs can be coadministered
without the need for dose adjustments. This implies that stan-
dard doses should be a starting point for the use of these
medications by HIV-infected patients. Additional pharmaco-
kinetic studies in a clinical setting are warranted to confirm the
findings of this study.
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